Stifel raised the firm’s price target on Johnson & Johnson to $165 from $155 and keeps a Hold rating on the shares following the Q2 report. The company upped earnings guidance with help from currency, sales strength, and a lower expected tariff impact, the analyst tells investors in a research note. The firm cites a sum-of-the-parts analysis for the target bump.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Johnson & Johnson’s Strong Q2 Performance and Growth Prospects Earn a Buy Rating
- Morning News Wrap-Up: Wednesday’s Biggest Stock Market Stories!
- Johnson & Johnson’s Strong Financial Performance and Strategic Positioning Earns Buy Rating
- Early notable gainers among liquid option names on July 16th
- Unusually active option classes on open July 16th